Cowen and Company reaffirmed their outperform rating on shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) in a report released on Saturday. The firm currently has a $100.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $150.00.
A number of other analysts have also commented on the company. Piper Jaffray Cos. set a $106.00 price objective on Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Thursday. Morgan Stanley lowered Alnylam Pharmaceuticals from an overweight rating to an equal weight rating and lowered their price objective for the stock from $38.00 to $36.00 in a research report on Friday. FBR & Co lowered their price objective on Alnylam Pharmaceuticals from $180.00 to $100.00 and set an outperform rating for the company in a research report on Thursday. Goldman Sachs Group Inc. reduced their target price on Alnylam Pharmaceuticals from $65.00 to $34.00 and set a neutral rating on the stock in a report on Thursday. Finally, Stifel Nicolaus reduced their target price on Alnylam Pharmaceuticals from $68.00 to $36.00 and set a hold rating on the stock in a report on Thursday. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $80.88.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Friday. The firm’s market cap is $2.94 billion. The company has a 50-day moving average price of $70.69 and a 200-day moving average price of $66.05. Alnylam Pharmaceuticals has a 12-month low of $33.16 and a 12-month high of $110.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.19. The firm earned $8.70 million during the quarter, compared to analyst estimates of $8.09 million. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The company’s revenue was up .2% on a year-over-year basis. During the same period last year, the company earned ($0.85) earnings per share. On average, analysts predict that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the sale, the chief executive officer now owns 148,465 shares in the company, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.00% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Aperio Group LLC boosted its stake in Alnylam Pharmaceuticals by 129.9% in the first quarter. Aperio Group LLC now owns 14,741 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 8,328 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at approximately $490,000. BlackRock Inc. boosted its stake in Alnylam Pharmaceuticals by 29.7% in the first quarter. BlackRock Inc. now owns 69,736 shares of the biopharmaceutical company’s stock valued at $4,377,000 after buying an additional 15,965 shares during the last quarter. BlackRock Group LTD boosted its stake in Alnylam Pharmaceuticals by 21.9% in the first quarter. BlackRock Group LTD now owns 519,834 shares of the biopharmaceutical company’s stock valued at $32,630,000 after buying an additional 93,450 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its stake in Alnylam Pharmaceuticals by 6.5% in the first quarter. BlackRock Fund Advisors now owns 1,838,376 shares of the biopharmaceutical company’s stock valued at $115,395,000 after buying an additional 112,252 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.